

Menopausal Changes in Body Fat Distribution and Metabolic Syndrome

Molly C. Carr, MD


University of Washington

May 26, 2004

Menopause

- **Changes in Metabolism**
 - body fat distribution
 - insulin resistance
- **Midlife Cholesterol Study**

Patterns of Body Fat Distribution




**Abdominal
(Android)**



**Lower Body
(Gynoid)**

Pre- vs. Postmenopausal Comparison of IAF



Menopausal Changes in Body Composition

- **± Weight**
- **↑ Total body fat (%)**
- **↓ LBM**
- **↑ Abdominal adiposity**
 - **↑ Waist circumference**
 - **↑ Truncal fat (DEXA scan)**
 - **↑ IAF (CT scan)**

Do Adipocyte-Derived Proteins Change with Menopause?

- **Adipocyte LPL** \pm Mauriege JCEM 2000, Ferrara JCEM 2002
- **Leptin** \pm DiCarlo et al. Gyn Endo 2002
- **Adiponectin** \uparrow Gavrilu et al. JCEM 2003
- **PAI-1** \uparrow Pfeilschifter et al. Endo Rev 2002
- **TNF- α** \uparrow Pfeilschifter et al. Endo Rev 2002
- **IL-6** \uparrow Pfeilschifter et al. Endo Rev 2002

Prevalence of Metabolic Syndrome Changes with Menopause

Features of the Metabolic Syndrome

- Central obesity
- Insulin Resistance
- Dyslipidemia
 - Elevated TG
 - Small dense LDL
 - Reduced HDL
- High Blood pressure
- Hypercoaguable state
- Proinflammatory state

NCEP ATP III: Identification of the Metabolic Syndrome


Positive diagnosis based on the presence of three or more of the following:

Risk Factor	Defining Level
Abdominal obesity (waist circumference [†])	
Men	>102 cm (>40 in)
Women	>88 cm (>35 in)
Triglycerides	≥150 mg/dL
HDL cholesterol	
Men	<40 mg/dL
Women	<50 mg/dL
Blood pressure	≥130/≥85 mm Hg
Fasting glucose	≥110 mg/dL


[†]Some male patients can develop multiple metabolic risk factors when waist circumference is only marginally increased (e.g., 94–102 cm [37–40 inches]).

Metabolic Syndrome: *Prevalence by ATP III Criteria* (NHANES III Population)

Overall 22% for age 20 years and older




Age-adjusted Prevalence of CHD in US Population (>50 y) - NHANES III



Midlife Cholesterol Study

OBSERVATIONAL ARM

INTERVENTIONAL ARM



Premenopausal → Postmenopausal

N = 120

Midlife Cholesterol Study

- **Endpoint measures**
 - LDL size
 - Fasting lipids
 - Hepatic lipase, LPL, CETP, PLTP
 - Visceral adiposity
 - Fasting insulin and glucose
 - Fibrinolytic/inflammatory factors (PAI-1, tPA, CRP, IL-6, SAA)

Summary: Postmenopause

- **Fasting lipids (↑LDL, ↑TG, ↓HDL, ↑sdLDL)**
- **Body fat distribution (↑ IAF)**
- **↑ Insulin and glucose levels**
- **↑ Prevalence of Metabolic Syndrome**


Limitations of current data

- **Most data cross-sectional**
- **Difficult to control for aging and BMI in cross-sectional studies**
- **Lack of control groups in prospective studies (women who remain premen during follow-up)**
- **Only one small prospective study assessing IAF by CT scan**

**Relationship of Menopausal
Status and Adiposity -
Summary of Research
Agenda**

Prevalence of Cardiovascular Diseases in Americans Age ≥ 20 by Age and Sex


United States: 1988-94



Summary: Postmenopause

- **Fasting lipids (↑LDL, ↑TG, ↓HDL, ↑sdLDL)**
- **Body fat distribution (↑ IAF)**
- **↑ insulin and glucose levels**
- **↑ thrombotic/inflammatory factors**
 - PAI-1, CRP, IL-6

Influence of the Menopause on Metabolism



Research Questions

- **Does abdominal fat preferentially increase with menopause?**
- **What factors influence this shift in body fat distribution (upstream)? (genetic, nutritional, physical inactivity, SES)**
- **Does the shift in body fat account partially or entirely for the changes in metabolism (lipid, insulin resistance/DM)?**
- **What is the mechanism by which HRT blocks the accumulation of central adipose tissue?**